Invivyd Inc (IVVD)
1.15
+0.11
(+10.58%)
USD |
NASDAQ |
Sep 27, 16:00
1.14
-0.01
(-0.87%)
After-Hours: 20:00
Invivyd Research and Development Expense (TTM): 149.33M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 149.33M |
March 31, 2024 | 162.62M |
December 31, 2023 | 158.66M |
September 30, 2023 | 116.31M |
June 30, 2023 | 120.87M |
March 31, 2023 | 114.38M |
Date | Value |
---|---|
December 31, 2022 | 179.21M |
September 30, 2022 | 227.72M |
June 30, 2022 | 242.96M |
March 31, 2022 | 240.89M |
December 31, 2021 | 182.89M |
September 30, 2021 | 121.72M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
114.38M
Minimum
Mar 2023
242.96M
Maximum
Jun 2022
168.13M
Average
160.64M
Median
Research and Development Expense (TTM) Benchmarks
NovaBay Pharmaceuticals Inc | 0.043M |
Palatin Technologies Inc | 25.13M |
iBio Inc | 5.185M |
Theriva Biologics Inc | 14.61M |
Oragenics Inc | 13.38M |